+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
R

Actively Recruiting

This research aims to evaluate the effectiveness and safety of different doses of the drug AP31969 in reducing the burden of Atrial Fibrillation AF. The trial is a randomized Phase 2 study comparing several doses of AP31969 against a placebo in adults diagnosed with paroxysmal or persistent AF. Participants are carefully selected based on their AF history and burden, and the study monitors heart rhythm using implanted devices. Participants are assigned randomly to one of five groups receiving oral tablets twice daily for 12 weeks AP31969 at doses of 100 mg, 200 mg, 350 mg, or 500 mg added later, or a placebo without active properties. The study consists of three main periods screening up to 4 weeks, treatment 12 weeks, and a follow-up period of 30 days, totaling about 20 weeks. During the study, participants receive an implantable loop recorder to continuously monitor heart rhythm. Throughout the trial, participants undergo several assessments including blood and urine tests, electrocardiograms, and continuous rhythm monitoring via the loop recorder. The main outcome measured is the AF burden from weeks 2 to 12, with additional measures including the number of AF episodes, quality of life changes, and ventricular tachycardia episodes. Safety and adherence are closely monitored, and the follow-up period helps assess sustained effects and participant well-being after treatment ends.

Age: 18Years +All GendersPhase 2
46 locations
T

Actively Recruiting

Researchers are evaluating two different approaches to treat functional Atrio-Ventricular Block AVB, a heart condition affecting electrical conduction. This trial compares the usual elective pacemaker PM implantation recommended by guidelines with a newer method involving cardiovascular autonomic tests CAT, electrophysiologic assessment EPS, and a procedure called cardioneuroablation CNA. The study aims to see if CNA can safely and effectively treat AVB without the need for a permanent pacemaker, validating current recommendations and exploring an alternative treatment option. The trial will include at least 100 participants aged 18 to 75 with AVB and a positive atropine test. Participants will be randomly assigned to receive either early pacemaker implantation Group A or undergo CATEPS followed by CNA with possible delayed pacemaker implantation if needed Group B. Those opting out of randomization enter a registry with personalized treatment choices. Group A will receive pacemakers with telemonitoring, while Group B will get implantable loop recorders and undergo CNA under general anesthesia. If CNA is unsuccessful, pacemaker implantation may follow. Participants will be involved for at least 12 months, undergoing regular check-ups at baseline, 3, 6, and 12 months. Assessments include ECG telemonitoring, quality of life and symptom questionnaires, and cardiovascular autonomic tests with telemedicine support. Safety will be closely monitored monthly, focusing on major cardiovascular events. The study uses telemonitoring devices and provides 247 contact with specialized medical staff. Data on symptoms, fatigue, depression, and sleep will also be collected to evaluate treatment effects comprehensively.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
2 locations
C

Actively Recruiting

Researchers are investigating the best way to treat patients with multivessel coronary artery disease or left main narrowing who experience symptoms of acute ischemia, specifically those with non-ST-segment elevation acute coronary syndrome NSTE-ACS. This trial compares two treatments percutaneous coronary intervention PCI with drug-eluting stents and coronary artery bypass grafting CABG. The study aims to understand which method offers better outcomes for patients with complex coronary artery disease who need early invasive treatment. The study enrolls patients with multivessel disease or left main coronary artery disease, eligible for invasive treatment and with a Syntax Score below 33. Participants will be randomly assigned to receive either PCI, involving fractional flow reserve or iFR measurements and optimized stent implantation, or CABG surgery, performed with techniques including on-pump or off-pump methods. Treatment decisions involve a Heart Team consultation, and both approaches aim for complete revascularization. The trial will follow patients over time to compare outcomes. Participants will have follow-up visits including cardiac echocardiography and stress tests after hospitalization. The study will monitor major adverse cardiac and cerebral events MACCE, serious adverse events, procedural complications, cost effectiveness, and heart function over one year and beyond. Secondary outcomes include bleeding, atrial fibrillation, heart failure, rehospitalization, and quality of life. The total study duration extends until 2030, with primary outcome assessment at one year.

Age: 18Years +All GendersPhase Not Applicable
9 locations